Regor Pharmaceuticals Inc.
Clinical trials sponsored by Regor Pharmaceuticals Inc., explained in plain language.
-
New pill shows promise for Tough-to-Treat breast cancer
Disease control Recruiting nowThis early-stage trial tests a new oral drug, RGT-419B, in people with a common type of advanced breast cancer (HR+, HER2-) that has worsened despite prior treatments. The study aims to find a safe dose and see if the drug works alone or with hormone therapy. About 64 adults with…
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 04:02 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check safety, find the right dose, and see if the dr…
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC